Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haematopoietic prostaglandin D synthase is a key cytosolic enzyme responsible for producing PGD₂ from PGH₂ via a glutathione-dependent mechanism. It plays central roles both as an effector molecule generator during immune responses—influencing leukocyte migration/cytokine production—and as a potential therapeutic target for diseases involving dysregulated inflammation such as asthma or allergy. Its unique structure among GSTs makes it distinct from other prostaglandin synthases found primarily within the CNS/lipocalins family.
Inhibition of PGD2 synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Haematopoietic Prostaglandin D Synthase (HPGDS).